Obesity with metabolic comorbidity — ABIM Board MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Metabolic-bariatric surgery discussion and anti-obesity pharmacotherapy options such as GLP-1 or dual incretin therapy
Adults with BMI at least 30, or at least 27 with weight-related comorbidity, are candidates for anti-obesity pharmacotherapy as adjunct to lifestyle therapy. BMI 35 or higher with comorbidities also warrants metabolic-bariatric surgery discussion.
Reference: AACE Obesity Guideline; ADA Standards of Care in Diabetes 2026